In this article, Dr. Xuemei Han, Director of Analytical Development at Tanvex CDMO, delves into the intricacies of analytical method development for biologics, shedding light on how Tanvex’s innovative approach to analytics can enable faster, more efficient timelines through:
- Platform Advantages: Platform analytical methods for streamlining development timelines for monoclonal antibodies (mAbs) and other biologic modalities.
- Differentiated Biosimilars Approach: Fit-for-purpose analytical strategies for biosimilars, ensuring regulatory compliance and analytical similarity.
- Cutting-Edge Tech: Revolutionary analytical capabilities for biopharma development – from ultra-high-pressure liquid chromatography to mass spectrometry, and beyond.
- Demonstrated Expertise: Extensive experience in biologics development, underpinned by comprehensive analytical solutions tailored to each biologic modality’s unique needs and timelines.
- Tailored Support: A client-centric, collaborative approach for building customized analytical strategies aligned with programs’ objectives and budgetary constraints.
Access the article
"*" indicates required fields